AtriCure (ATRC) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY26 EPS Guidance
Tweet
Share
E-mailGet Alerts ATRC Hot Sheet
Price: $53.73 +4.29%
EPS Growth %: -300.0%
Financial Fact:
Other: -32K
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: -300.0%
Financial Fact:
Other: -32K
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
AtriCure (NASDAQ: ATRC) reported Q2 EPS of $0.18, $0.19 better than the analyst estimate of ($0.01). Revenue for the quarter came in at $153.6 million versus the consensus estimate of $151.84 million.
GUIDANCE:
AtriCure sees FY2026 EPS of $0.24-$0.32, versus the consensus of $0.12.
For earnings history and earnings-related data on AtriCure (ATRC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Casey's General Stores (CASY) Tops Q1 EPS by 69c
- BMO Capital Starts American Eagle Outfitters (AEO) at Market Perform
- ABM Industries (ABM) Reports In-Line Q3 EPS; raises guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
